Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 6/20 | 0.41 |
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.41 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | AOC2 | O75106 | 5/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30626440 | 1.00 | NISCH (0.44) | NISCHPLAUMAOAMAOBAOC2 | |
| Hydrochloric Acid SCHEMBL29433093 | 1.00 | NISCH (0.44) | NISCHPLAUMAOAMAOBAOC2 | |
| Hydrochloric Acid SCHEMBL25223662 | 1.00 | NISCH (0.44) | NISCHPLAUMAOAMAOBAOC2 | |
| Hydrochloric Acid SCHEMBL21810813 | 1.00 | NISCH (0.44) | NISCHPLAUMAOAMAOBAOC2 | |
| SCHEMBL29433047 | 0.98 | PLAU (0.45) | NISCHPLAUMAOAMAOBAOC2 | |
| SCHEMBL447509 | 0.98 | PLAU (0.45) | NISCHPLAUMAOAMAOBAOC2 | |
| SCHEMBL14120418 | 0.98 | PLAU (0.45) | NISCHPLAUMAOAMAOBAOC2 | |
| SCHEMBL14121578 | 0.98 | PLAU (0.45) | NISCHPLAUMAOAMAOBAOC2 | |
| Hydrochloric Acid SCHEMBL10460312 | 0.83 | MAOA (0.54) | PLAUMAOAMAOBAOC2DAO | |
| Quinoline SCHEMBL5583721 | 0.80 | ALDH1A1 (0.47) | NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2025-09-23 | — | — | US | disclosed |
| CN-118525003-A | Novel heteroaryl urea compounds as KV7.2 inhibitors | 伊卡根有限责任公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3851436-B1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | KAKEN PHARMA CO LTD (JP) | 2024-06-12 | — | — | EP | disclosed |
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | US | disclosed |
| EP-3851436-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 2021-07-21 | — | — | EP | disclosed |
| CN-112689636-A | Novel heteroatom aromatic amide derivative and drug containing the same | 科研制药株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-107207476-B | Indole and azaindole derivatives and their use in neurodegenerative diseases | 默克专利有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | disclosed |
| EP-1908760-A1 | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | Portela & Ca., S.A. (PT) | 2008-04-09 | — | — | EP | disclosed |
| US-7259271-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2007-08-21 | — | — | US | disclosed |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | PORTELA & C.A., S.A. (PT) | 2007-01-18 | — | — | US | disclosed |
| US-7125904-B2 | Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2006-10-24 | — | — | US | disclosed |
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | ABBVIE INC. | 2006-06-15 | — | — | US | disclosed |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | PORTELA & C.A., S.A. (PT) | 2004-07-22 | — | — | US | disclosed |
| WO-2004033447-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PERIPHERALLY-SELECTIVE INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE | PORTELA & C.A., S.A. (PT) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408038-A2 | Imidazole deriviatives and their use as peripherally-selective inhibitors of dopamine-beta-hydroxylase | Portela & Ca., S.A. (PT) | 2004-04-14 | — | — | EP | disclosed |
| US-4683223-A | ANTIINFLAMMATORY, HYPOTENSIVE, ANTIPSYCHOTIC | WARNER-LAMBERT COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| EP-0181109-A2 | N6-benzopyrano- and benzothiopyrano-adenosines | WARNER-LAMBERT COMPANY (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128689-A1 | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof | CACNA1E, CACNA1D, CACNA1S | MAOA 2513/4885MAOB 2316/4885SIGMAR1 175/4885 |
| US-20040142996-A1 | Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation | DBH, ADRB1, ADRB3 | MAOA 105/4885MAOB 40/4885SIGMAR1 116/4885 |
| US-20230086366-A1 | Novel heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | MAOA 441/4885MAOB 378/4885SIGMAR1 224/4885 |
| US-12421225-B2 | Heteroaromatic amide derivative and medicament containing the same | SCN7A, HCN4, SCN4A | MAOA 326/4885MAOB 327/4885SIGMAR1 188/4885 |
| US-20070015730-A1 | Peripherally-Selective Inhibitors of Dopamine-ß-Hydroxylase And Method Of Their Preparation | DBH, PAH, TH | MAOA 43/4885MAOB 26/4885SIGMAR1 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.